Lois E. Shepherd

10 Stuart St
Kingston, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 153 publications

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancer.

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancer.

Journal: medRxiv : the preprint server for health sciences

Published: July 10, 2026

Correlation of pelvic magnetic resonance imaging with diagnostic loop electrosurgical excision procedure/cone biopsy and hysterectomy pathology: an exploratory analysis of the CX.5/SHAPE trial.

Correlation of pelvic magnetic resonance imaging with diagnostic loop electrosurgical excision procedure/cone biopsy and hysterectomy pathology: an exploratory analysis of the CX.5/SHAPE trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 11, 2026

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Journal: Current oncology (Toronto, Ont.)

Published: April 29, 2026

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2026

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Journal: Blood neoplasia

Published: January 09, 2026

Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.

Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.

Journal: JNCI cancer spectrum

Published: December 17, 2025

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.

Journal: Journal of medical Internet research

Published: November 29, 2025

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

Journal: JNCI cancer spectrum

Published: November 17, 2025

Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.

Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.

Journal: Gynecologic oncology

Published: November 16, 2025

The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations.

The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 21, 2025

Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations.

Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 21, 2025

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Journal: Blood advances

Published: September 24, 2025

Showing 1-12 of 153

Last Updated: 09/26/2026